TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06630260
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide will be supplied as 5, 20, 100, 140, 180 or 250 mg hard capsules.
Study: NCT05447546
Drug: HT-6184
Normalized name: 5-HT
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT05447546
Drug: HT-6184 Placebo
Normalized name: 5-HT
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT06695013
Drug: zanubrutinib
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: zanubrutinib 160 mg BID orally
Study: NCT06695013
Drug: CAR-T
Normalized name: CD5CAR-T
DrugBank: Anti-CD5 CAR T-cell therapy (DB17279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAR-T Cell therapy
Study: NCT06695013
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg IV Q3-4W
Study: NCT06628713
Drug: Sebetralstat
Normalized name: Sebetralstat
DrugBank: Sebetralstat (DB18305)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Plasma Kallikrein Inhibator
Study: NCT06629259
Drug: Guanfacine Extended Release (XR)
Normalized name: guanfacine Extended Release Oral Tablet
DrugBank: Guanfacine (DB01018)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3mg tablet once daily
Study: NCT06629779
Drug: PF-06821497
Normalized name: PF-06821497
DrugBank: PF-06821497 (DB14799)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral continuous
Study: NCT06629779
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral continuous
Study: NCT06688123
Drug: SHR-3167
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 1.
Study: NCT06688123
Drug: SHR-3167
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 2.
Study: NCT06688123
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose level 3.
Study: NCT05550246
Drug: Atomoxetine
Normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment given for 3 nights
Study: NCT05550246
Drug: Oxybutynin
Normalized name: Oxybutynin
DrugBank: Oxybutynin (DB01062)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment given for 3 nights
Study: NCT04894474
Drug: BI 767551 intravenous
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 767551 intravenous
Study: NCT04894474
Drug: BI 767551 inhalation
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 767551 inhalation
Study: NCT06629584
Drug: Asciminib
Normalized name: Asciminib
DrugBank: Asciminib (DB12597)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will receive asciminib 80 mg PO once daily continuously for 28-day cycles for 2 years.
Study: NCT06630390
Drug: Daridorexant 50 mg
Normalized name: daridorexant 50 MG
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered consistent with labeling from the US Food and Drug Administration.
Study: NCT06687070
Drug: APG -2449
Normalized name: APGA
DrugBank: Aminopterin (DB08878)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally once a day(QD), every 28 days as a cycle.
Study: NCT06688786
Drug: neoadjuvant mFOLFOX6 chemotherapy combined with PD-1 inhibitor therapy
Normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative treatment with 4-6 cycles of mFOLFOX6 regimen combined with serplulimab
Study: NCT06686082
Drug: Biologics
Normalized name: COVID-19 Therapeutic Biologics - Spike-GM-CSF Protein Lactated Ringer's Injection
DrugBank: COVID-19 Spike-GM-CSF Protein Lactated Ringer's Injection (DB16520)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The ultrasonic changes of synovitis and enthesitis were observed after 12 weeks of treatment with biologic agents
Study: NCT06690424
Drug: Remimazolam
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: remimazolam 0.2mg / kg was injected IV during the induction of anesthesia，and remimazolam 0.3-0.5mg / kg / h was administered IV during anesthesia maintenance.
Study: NCT06690424
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 1.5-2mg / kg was injected IV during the induction of anesthesia，and Propofol 2-3mg / kg / h was administered IV during anesthesia maintenance.
Study: NCT04840394
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab is a potent humanized monoclonal antibody with high specificity of binding to the PD 1 receptor. Pembrolizumab has an acceptable preclinical safety profile and is approved as an IV therapy for a variety of advanced malignancies.
Study: NCT04278729
Drug: Apixaban 5 MG
Normalized name: apixaban 5 MG
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 - 5 mg tablet taken orally twice a day
Study: NCT04939480
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab 1200 mg intravenous solution
Study: NCT06636032
Drug: AdMSC (CellReady®)
Normalized name: adMSC
DrugBank: Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins (DB15729)
Approvals — FDA: no, EMA: no, PMDA: no
Description: At day 0, patients will have AdMSC injections. Patients will be followed-up for 6 months
Study: NCT06634667
Drug: third-generation EGFR-TKI combined with anlotinib
Normalized name: miconazole
DrugBank: Anlotinib (DB11885)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: third-generation EGFR-TKI combined with anlotinib as maintenance therapy following 4 to 6 cycles of chemotherapy and immunotherapy until progressive disease.
Study: NCT05054478
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daratumumab added to induction, first consolidation and second consolidation
Study: NCT06039254
Drug: HRS-1780
Normalized name: HRS-1167
DrugBank: HRS-1167 (DB18703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose in each arm
Study: NCT05931393
Drug: Cabozantinib 80 MG
Normalized name: cabozantinib 80 MG
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: cabozantinib 80mg daily
Study: NCT05454241
Drug: Anti-CD7 CAR-T
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Universal CAR-T cells targeting CD7
Study: NCT05590234
Drug: Dexmedetomidine injection
Normalized name: dexmedetomidine Injection
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1ug/kg dexmedetomidine plus 20 mL of bupivacaine 0.25%
Study: NCT05590234
Drug: Bupivacaine 0.25% Injectable Solution
Normalized name: BUPivacaine 0.25% injectable solution
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 ml of bupivacaine 0.25%,
Study: NCT06149806
Drug: Sacubitril / Valsartan Oral Tablet [Entresto]
Normalized name: sacubitril / valsartan Oral Tablet [Entresto]
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: efficacy and tolerability of Sacubitril/Valsartan in the treatment of chronic heart failure on complex congenital cardiopathy
Study: NCT04897503
Drug: Riboflavin
Normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Corneal epithelium removed followed by riboflavin drop administration (riboflavin/dextran -vs- riboflavin/methylcellulose) every 2 minutes for 30 minutes followed by UV light exposure with additional riboflavin administration every 2 minutes for 30 minutes. Subjects will be randomized to receive either the riboflavin/dextran solution or the riboflavin/HPMC solution.
Study: NCT00000800
Drug: Methadone hydrochloride
Normalized name: Methadone Hydrochloride
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000800
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04997837
Drug: PD-1 inhibitor
Normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab/Toripalimab 240mg solution intravenously once daily, Q2W. OR Nivolumab/Toripalimab 360mg solution intravenously once daily, Q3W; OR Pembrolizumab/Tilelizumab/Sintilimab/Carrelizumab, 200mg solution intravenously once daily, Q3W.
Study: NCT04997837
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CapeOx: 130 mg/m2 (body surface area) solution intravenously once-daily, followed by 20 days off.~FOLFOX: 85 mg/m2 (body surface area) solution intravenously once-daily, followed by 13 days off.
Study: NCT04997837
Drug: Tegafur-gimeracil-oteracil potassium
Normalized name: tegafur
DrugBank: Oteracil (DB03209)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: SOX: 40 - 60 mg bid orally in 14 days, followed by 7 days off
Study: NCT04997837
Drug: 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: FOLFOX：2400-2800mg/m2/d continuous intravenous pumping for 48h, Q2W
Study: NCT00002410
Drug: Indinavir sulfate
Normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002410
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00002410
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04556084
Drug: Blinatumomab
Normalized name: Blinatumomab
DrugBank: Blinatumomab (DB09052)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Blinatumomab will be given as a 28-day continuous infusion with 14-days in between Cycle 1 and Cycle 2 as per the package insert and FDA approved labeling.~Patient weight greater than or equal to 45kg will receive 28 mcg/day~Patient weight less than 45kg will receive 15 mcg/m2/day
Study: NCT04567420
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 4 week cycles
Study: NCT04567420
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4 week cycles
Study: NCT05458674
Drug: Tucatinib
Normalized name: Tucatinib
DrugBank: Tucatinib (DB11652)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: taken orally
Study: NCT05458674
Drug: Eribulin
Normalized name: Eribulin
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: taknen intravenously
Study: NCT05458674
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: taken intravenously
Study: NCT06701201
Drug: SynKIR-110
Normalized name: SynKIR-110
DrugBank: SynKIR-110 (DB17365)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous T cells Transduced with Mesothelin KIR-CAR
Study: NCT06701201
Drug: SynKIR-310
Normalized name: SynKIR-110
DrugBank: SynKIR-110 (DB17365)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous T Cells transduced with CD19 KIR-CAR
Study: NCT06005714
Drug: Mindeudesivir hydrobromide tablets and Cyclosporine softgels
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindeudesivir hydrobromide tablets are administered once at D1 and D4, and cyclosporine sofgels are administered once at D4.
Study: NCT00002206
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT05890638
Drug: Ipratropium / Levosalbutamol Fixed Dose Combination
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: New combination test treatment
Study: NCT05890638
Drug: Ipratropium + Levosalbutamol Free Dose Combination
Normalized name: ipratropium Metered Dose Inhaler
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Free combination control treatment
Study: NCT04547296
Drug: Sodium Bicarbonate Ringer's Solution
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After the participants enter the operating room, radial artery puncture and catheterization were performed. The blood gas in the non-oxygen state was used as the basic value. A peripheral venous access was established in one upper limb, and the two groups were pre-dilated with sodium bicarbonate Ringer's solution or acetate Ringer's solution (30 min, 8 ml/kg). For laparoscopic surgery, adjust the PaCO2 value to 35-45 mmHg again 10 minutes after the establishment of the pneumoperitoneum. After the operation started, the two groups of participants were maintained with 4-5 ml/kg/h Ringer's solution during the operation. Blood gas was measured every hour after tracheal intubation during the operation, and the last blood gas was measured when the skin was sutured. When the blood gas pH \<7.2, 5% sodium bicarbonate injection was given to correct it.
Study: NCT06423781
Drug: BHV-7000
Normalized name: BHV-5000
DrugBank: BHV-5000 (DB17817)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BHV-7000 75 mg taken once daily
Study: NCT04149210
Drug: Fluorometholone 0.1% Oph Susp
Normalized name: FLUOROMETHOLONE 0.1% OPH SUSP
DrugBank: Fluorometholone (DB00324)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: fluorometholone 0.1% one drop twice daily for four weeks, beginning with one drop just before trachomatous trichiasis surgery on the upper lid.
Study: NCT04149210
Drug: Artificial Tears
Normalized name: Artificial Tears
DrugBank: Propylene glycol (DB01839)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Artificial tears (placebo) given one drop twice daily for four weeks, beginning with one drop just prior to trachomatous trichiasis surgery on the upper lid.
Study: NCT04539808
Drug: Irinotecan Hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04539808
Drug: Losartan Potassium
Normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04539808
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04717700
Drug: Selinexor 20 MG Oral Tablet
Normalized name: Selinexor 20 MG Oral Tablet
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Comparing an alternating regimen of selinexor-lenalidomide/bortezomib-dexamethasone to standard bortezomib-lenalidomide-dexamethasone
Study: NCT04717700
Drug: Bortezomib Injection
Normalized name: bortezomib Injection
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Comparing an alternating regimen of selinexor-lenalidomide/bortezomib-dexamethasone to standard bortezomib-lenalidomide-dexamethasone
Study: NCT04717700
Drug: Lenalidomide capsule
Normalized name: Lenalidomide Capsules
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Comparing an alternating regimen of selinexor-lenalidomide/bortezomib-dexamethasone to standard bortezomib-lenalidomide-dexamethasone
Study: NCT04717700
Drug: Dexamethasone Oral
Normalized name: dexamethasone Oral Tablet
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Comparing an alternating regimen of selinexor-lenalidomide/bortezomib-dexamethasone to standard bortezomib-lenalidomide-dexamethasone
Study: NCT04274361
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine infusion
Study: NCT05781698
Drug: Mesalamine
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mesalamine is the cornerstone used for the treatment of mild to moderate ulcerative colitis
Study: NCT05781698
Drug: Fenofibrate
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fibrates, which are specific pharmacological agonists of PPARα, have been widely used in the treatment for hypercholesterolemia and hypertriglyceridemia
Study: NCT06709014
Drug: buntanetap/posiphen
DrugBank: Posiphen (DB15317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30mg capsule by mouth once daily for 18 months
Study: NCT04850040
Drug: Apatinib Mesylate
Normalized name: mesylate
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg, oral every other day. Approximately half an hour after a meal (the daily dose should be taken at the same time as possible) with warm boiled water.
Study: NCT04850040
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg, 30 minutes intravenous drip (overall dosing time no shorter than 20 minutes and no longer than 60 minutes, including tube flush time) once every 2 weeks, with the first dose administered concurrently with Apatinib Mesylate Tablets.
Study: NCT04850040
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 85 mg/m2, once every 2 weeks, to be administered half an hour after Camrelizumab injection.
Study: NCT03876262
Drug: Moxidectin
Normalized name: moxidectin
DrugBank: Moxidectin (DB11431)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2mg tablets, encapsulated for blinding
Study: NCT03876262
Drug: Ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3mg tablets, encapsulated for blinding
Study: NCT06362694
Drug: Dabrafenib + Trametinib
Normalized name: Dabrafenib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dabrafenib is an inhibitor of some mutated forms of BRAF kinases. Trametinib is a reversible inhibitor of mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 activation and of MEK1 and MEK2 kinase activity. Dabrafenib and trametinib target two different kinases in the RAS/RAF/MEK/ERK pathway. Use of dabrafenib 623 and trametinib in combination resulted in greater growth inhibition of BRAF V600 mutation-positive tumors.
Study: NCT06626035
Drug: Methadone based ERAS
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Children randomized to the methadone arm will receive standardized perioperative care and analgesia, including intraoperative intravenous methadone (0.1 mg/kg up to a maximum of 5 mg before incision \[pre-CPB in CS\] and 0.05 mg at the end of surgery \[after CPB in CS\]) and postoperatively, up to 4 oral doses of methadone every 12 hours before discharge as part of standardized multimodal analgesia in the hospital setting.
Study: NCT06626035
Drug: SOC non-methadone based group
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Children randomized to the standard-of-care arm will receive standard opioid analgesia protocol without intra- and post-operative methadone per the current site standards.
Study: NCT04772365
Drug: SHR-1819
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1819 will be subcutaneously administered with different dose levels;
Study: NCT06627322
Drug: Dual-combination therapy
Normalized name: Tums Dual Action
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group 1: Metformin/DPP-4i-based or Metformin/SGLT2i-based dual-combination therapy. Any oral antiglycemic drugs on the market.
Study: NCT05684978
Drug: Perampanel
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The purpose of this study is to determine the efficacy of Perampanel, an approved antiseizure medication, in the treatment of refractory status epilepticus (RSE), to identify determinants of outcomes, and establish safety.
Study: NCT06397872
Drug: 100 mg Resmetirom Tablet
Normalized name: resmetirom 100 MG
DrugBank: Resmetirom (DB12914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily oral dose for 6 days
Study: NCT06689163
Drug: HRS-1167 tablets
Normalized name: HRS-1167
DrugBank: HRS-1167 (DB18703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS-1167 tablets
Study: NCT06689163
Drug: Abiraterone Acetate tablets（II）
DrugBank: Abiraterone (DB05812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abiraterone Acetate tablets（II）
Study: NCT06689163
Drug: Prednisone Acetate tablets
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone Acetate tablets
Study: NCT06690138
Drug: Divarasib
Normalized name: Divarasib
DrugBank: Divarasib (DB17488)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divarasib will be administered as a single oral dose as specified for the respective period.
Study: NCT06690138
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole will be administered BID on Day 1 and QD from Day 2 to 13 and as specified for the respective period.
Study: NCT04982432
Drug: Orismilast
Normalized name: Orismilast
DrugBank: Orismilast (DB19042)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orismilast is a next generation PD4 inhibitor with demonstrated broad anti inflammatory properties
Study: NCT06453447
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg PO once daily for 14 days starting day of surgery
Study: NCT05366933
Drug: Vitamin B-Complex Supplement
Normalized name: vitamin B complex
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B-Complex Supplement containing: 5-methyltetrahydrofolate, riboflavin 5 phosphate, pyridoxal phosphate, and methylcobalamin
Study: NCT06468436
Drug: Dexmedetomidine-Esketamine Combination
Normalized name: esketamine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: For patients with invasive ventilation, nighttime sedation (20:00-06:00) is provided with an initial infusion rate of \[0.05×kg\] ml/h which is increased by \[0.025×kg\] ml/h every 10 min, until the Richmond Agitation-Sedation Scale (RASS) reaches -2 to -1, maximal infusion rate reaches \[0.175×kg\] ml/h, or adverse reactions occur. Daytime sedation (06:00-20:00) is provided as above when considered necessary by the ICU physicians, with a target RASS score of -2 to +1.~For patients with non-invasive ventilation (including high-flow nasal oxygenation) or without assisted ventilation, nighttime sedation (20:00-06:00) is provided with an initial infusion rate of \[0.0125×kg\] ml/h which is increased by \[0.0125×kg\] ml/h every 10 min, until the RASS reaches -1, maximal infusion rate reaches \[0.05×kg\] ml/h, or adverse reactions occur. Daytime sedation (06:00-20:00) is typically not required but is provided when considered necessary by the ICU physicians, with a target RASS score of -1 to +1.